1. Kuehn Law is investigating fiduciary duty breaches at Tempus AI. 2. Insiders have misrepresented revenue sources related to AI solutions. 3. Tempus AI generated revenue mainly through acquisitions and data agreements. 4. Concerns arise over contract integrity with AstraZeneca and others. 5. Shareholders from before August 2024 should contact Kuehn Law.
The investigation into fiduciary breaches can harm investor confidence, affecting stock price. Previous cases indicate that similar actions often lead to declines, as seen in firms like Theranos and Nikola.
Given the ongoing investigation and implications for fiduciary responsibilities, it's crucial for current investors to stay informed. This could impact TEM's stock performance significantly.
The investigation's publicity may lead to immediate sell-offs, but long-term impact depends on outcomes. Past examples show rapid reactions to litigation news, as witnessed with companies facing SEC investigations.
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Tempus AI, Inc. (NASDAQ:TEM) breached their fiduciary duties to shareholders.
According to a federal securities lawsuit, Insiders at Tempus AI caused the company to brand itself as an AI company despite having little history of generating significant revenues from AI solutions; instead, the Company generated most of its revenues from acquisitions, genomic testing and data licensing agreements. Insiders repeatedly claimed that the contract value and quality of its data licensing agreements with life science companies were secure and expanding. The Company often reported on its relationship with long-term customer AstraZeneca as an example. Importantly, Tempus announced an expanding contract with AstraZeneca via a joint venture between the Company, AstraZeneca and Pathos AI. The Company similarly announced a joint venture with SoftBank as a way to generate revenue growth by entering the Japanese market. Tempus additionally claimed high revenue potential for Ambry Genetics ("Ambry"), a target it acquired. The Company claimed that Ambry's accelerated growth was on account of its strong relationships with health care providers.
If you currently own TEM and purchased prior to August 6, 2024 please contact Justin Kuehn, Esq. here, by email at justin@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law
(833) 672-0814
View original content to download multimedia:https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-tempus-ai-inc-to-contact-law-firm-302561638.html
SOURCE Kuehn Law, PLLC